Biopharmaceutical benchmarks 2014 (original) (raw)

Nature Biotechnology volume 32, pages 992–1000 (2014)Cite this article

Subjects

Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: Approvals by region and by date.

The alternative text for this image may have been generated using AI.

Figure 2: mAbs approved within the indicated periods, expressed as a percentage of total biopharmaceutical product approvals within the same period.

The alternative text for this image may have been generated using AI.

Figure 3: Product approvals, cumulative (1982–2014) and for the current period (2010–July 2014) in the context of product class.

The alternative text for this image may have been generated using AI.

Figure 4

The alternative text for this image may have been generated using AI.

Figure 5: Expression systems used to manufacture biopharmaceutical products.

The alternative text for this image may have been generated using AI.

References

  1. Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24, 769–776 (2006).
    Article CAS Google Scholar
  2. Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).
    Article CAS Google Scholar
  3. Blackstone, E. & Fuhr, J. The Economics of biosimilars. American Health and Drug Benefits (July 2, 2014).
    Google Scholar
  4. Rickwoood, S. & Di Biase, S. Searching for Terra Firma in the Biosimilars and Non-Original Biologics Market (IMS Health, Parsippany, NJ, USA, 2013).
    Google Scholar
  5. Hospira Reports on success of its biosimilar proteins in Europe and Australia, La Meire Biologics 6, 3–4 (2013).
  6. Dalgaard, K. et al. Biosimilars Seven Years On: Where are We and What's Next? (McKinsey and Company, New York, NY, USA, 2013).
    Google Scholar
  7. Perez, H.L. et al. Antibody–drug conjugates: current status and future directions. Drug Discov. Today 19, 869–881 (2014).
    Article CAS Google Scholar
  8. Goede, V. et al. Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results of the CLL11 Trial. Presented at the 55th ASH Annual Meeting and Exposition. New Orleans, LA. December 7-10, 2013. Abstract 6.
  9. Nielsen, L.S. et al. Single-batch production of recombinant human polyclonal antibodies. Mol. Biotechnol. 45, 257–266 (2010).
    Article CAS Google Scholar
  10. Kling, J. Sanofi to propel inhaled insulin Afrezza to market. Nat. Biotechnol. 32, 851–852 (2014).
    Article CAS Google Scholar
  11. Kwon, K.C. et al. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65, 782–799 (2013).
    Article CAS Google Scholar
  12. Emerton, D.A. Profitability in the biosimilars market: can you translate scientific excellence into a healthy commercial return? Bioprocess Int. 11, 6–14 (2013).
    Google Scholar
  13. Brennan, T.A. & Wilson, J.M. The special case of gene therapy pricing. Nat. Biotechnol. 32, 874–876 (2014).
    Article CAS Google Scholar
  14. PhRMA. Medicines in Development: Biologics. 2013 report. http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf (PhRMA, Washington, DC, 2013)
  15. Olinger, G.G. et al. Delay treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus monkeys. Proc. Natl. Acad. Sci. USA 109, 18030–18035 (2012).
    Article CAS Google Scholar
  16. Qui, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 10.1038/nature13777 (29 August 2014).
  17. Broz, A., Huang, N. & Unruh, G. Plant-based protein biomanufacturing. Genet. Eng. Biotechnol. News 33, 32–33 (2013).
    Article Google Scholar
  18. Beck, A. & Reichert, J.M. Approval of the first biosimilar antibodies in Europe. MAbs 5, 621–623 (2013).
    Article Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Chemical and Environmental Sciences, Gary Walsh is at the Industrial Biochemistry Program, University of Limerick, Ireland, and the Materials and Surface Science Institute, University of Limerick, Ireland.,
    Gary Walsh

Corresponding author

Correspondence toGary Walsh.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Walsh, G. Biopharmaceutical benchmarks 2014.Nat Biotechnol 32, 992–1000 (2014). https://doi.org/10.1038/nbt.3040

Download citation

This article is cited by